期刊文献+

中国人CYPC19和CYP2C9等位基因多态性分析 被引量:7

下载PDF
导出
摘要 目的 探讨细胞色素P450(CYP)2C19(CYP2C19)和CYP2C9在中国人群中的等位基因多态性分布,分析影响上述基因多态性的因素。方法 应用聚合酶链反应-变性高效液相(PCR-DHPLC)技术分析了150例癫痫患者CYP2C19外显子4(·3)、外显子5(·2)和CYP2C9外显子7(·3)的等位基因变异,现察这二种基因多态性在癫痫患者中分布的特征。结果 150例 癫痫患者CYP2C19·3、CYP2C19·2和CYP2C9·3均为野生型的发生率为38.7%,CYP2C19·2、CYP2C19·3和CYP2C9·3等位基因频率分别为34.3%、5.3%和7.3%.CYP2C19·2和CYP2C19·3等位基因分布频率存在性别之间的显著差异,p值分别为p<0.05、p<0.01;而CYP2C9·3的等位基因分布频率不存在性别之间的显著差异。CYP2C19基因型存在性别之阍的差异显著,p<0.01。存在CYP2C9·3等住基因多态性的个体一定出现CYP2C19·2的等住基因多态性。结论 性别因素可能对CYP2C19酶的活性产生影响,应用同时经CYP2C9和CYP2C19代谢的药物时,需进行基因型测定。
出处 《哈尔滨医药》 2002年第4期1-3,共3页 Harbin Medical Journal
  • 相关文献

参考文献12

  • 1de Morals SMF,Wilkinson GR,Blaisdell J,et al. The major genetic defect responsible for the polymorphism of S--mephenytoin metabolism in humans. J Biol Chem, 1994,269(22): 15419-15422.
  • 2de Morals SMF, Wilkinson GR, Blaisdell J ,et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol, 1994,46(4) :594-598.
  • 3Imai J,leiri I. Mamiya K. Et al. Polymorphism of the cytochrome P450(CYP) 2C9 gene in Japanese epilepsy patients :genetic analysis of the CYP2C9 locus. Pharmacogenetics,2000,10(1) :85--89.
  • 4陈彪,黄越,杨静芳,等.DHPLC方法检测CYP2C9的基因型.待发表.
  • 5Miyuke Kimura, Ichiro leiri, Kohsuke Mamiya, et al. Genetic Polymorphism of cytochrome P450s,CYP2C19,and CYP2C9 in a Japanese Population. Ther Drug Mont,1998,20(3) :243-247.
  • 6Mamiya K,Hadama A,Yukawa E,leiri l,et al. CYP2C19 polymorphism effect on phenobarbitone. Eur J Clin Pharmacol, 2000,55(11-12) :821-825.
  • 7Miyuki Kimura, Ichiro leiri, Kohsuke Mamiya ,et al. Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese Population. Ther Drug Monit, 1998,20(3) : 243-247.
  • 8Kunihido Itoh, Kazuyuki Inoue, Hiroshi Nakao,et al. Polymerase Chain Reaction- Single- Strand Conformation Polymorphism Based Determination of Two Major Genetic Defects Responsible for a Phenotypic Polymorphism of Cytochrome P450(CYP) 2C19 in the Japanese Population. Analytical Biochemistry, 2000,284(1) :160-162.
  • 9Yoon YR,Shon JH, Kim MK,et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol, 2001 ; 51 (3) : 277 - 280.
  • 10Ichiro leiri, Hitoshi Tainaka, Toshihiro Morita, et al. Catalytic Activty of Three Variants (Ile, Leu, and Thr) et Amiino Acid Residue 359 in Human Cyp2C9 gene and Simultaneous Detection Using Single-Strand Conformation Polymorphism Analysis. Therapeutic Drug Monitoring, 2000 , 22 (3) : 237-244.

同被引文献77

  • 1黄越,杨静芳,齐晓涟,王育琴,王维治,陈彪.CYP2C19和CYP2C9基因型与苯妥英血药浓度关系的研究[J].中华医学杂志,2004,84(20):1686-1689. 被引量:17
  • 2王红,聂玉强,戴寿军,佘庆珠,李瑜元.质子泵抑制剂抑酸效果与肝药酶基因型的关系[J].中华内科杂志,2003,42(11):777-780. 被引量:5
  • 3陈騉,王睿,文思远,李健,王升启.用基因芯片技术测定健康人群P4502C9基因多态性[J].中国临床药理学杂志,2005,21(3):176-179. 被引量:10
  • 4胡祥鹏,黄庆科,马升高,吴明,吴金明,吴建胜.浙江省汉族人群CYP2C19基因多态性的分布特征[J].浙江医学,2009(10). 被引量:7
  • 5Internationgal Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori. In Schistosomes, liver flukes and Helicobacter pylori. IARC Lyon, 1994, 177-202.
  • 6Kawabata H, Habu Y, Tomioka H, et aI. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxieillin and clarithromycin. Aliment Pharmacol Ther, 2003, 17:259-264.
  • 7Egan LJ, Myhre GM, Mays DC, et al. CYP2C19 pharmacoge netics in the clinical use of proton pump inhibitors for gastro- oesophageal reflux disease:variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment-Pharmacol Ther, 2003, 17:1521-1528.
  • 8Barbara GS, Joanna W, Teresa S, et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid related disorders with Helieobaeter. pylori infection. Eur J Clin Pharmacol, 2005, 61: 375-379.
  • 9Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'hydroxylation. Arch Biochem Biophys, 1993, 306: 240-245.
  • 10De Morals SMF, Wiekimon GR, Blaidell J, et al. The maior genetic defect responsible for the polymorphism of S mephenytoin in human. JBiolChem, 1994, 269:15149-15422.

引证文献7

二级引证文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部